These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 33039388)
21. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Wettersten HI; Hakimi AA; Morin D; Bianchi C; Johnstone ME; Donohoe DR; Trott JF; Aboud OA; Stirdivant S; Neri B; Wolfert R; Stewart B; Perego R; Hsieh JJ; Weiss RH Cancer Res; 2015 Jun; 75(12):2541-52. PubMed ID: 25952651 [TBL] [Abstract][Full Text] [Related]
22. Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges. Lai JZ; Lai HH; Cao D Anticancer Res; 2018 Jun; 38(6):3757-3761. PubMed ID: 29848739 [TBL] [Abstract][Full Text] [Related]
23. Automated Machine Learning and Explainable AI (AutoML-XAI) for Metabolomics: Improving Cancer Diagnostics. Bifarin OO; Fernández FM J Am Soc Mass Spectrom; 2024 Jun; 35(6):1089-1100. PubMed ID: 38690775 [TBL] [Abstract][Full Text] [Related]
24. MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis. Gu L; Li H; Chen L; Ma X; Gao Y; Li X; Zhang Y; Fan Y; Zhang X Oncotarget; 2015 Oct; 6(32):32545-60. PubMed ID: 26416448 [TBL] [Abstract][Full Text] [Related]
26. CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma. Tulchiner G; Brunner A; Schmidinger M; Staudacher N; Orme JJ; Thurnher M; Horninger W; Culig Z; Pichler R BJU Int; 2021 Jul; 128(1):29-32. PubMed ID: 33455021 [No Abstract] [Full Text] [Related]
27. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer. Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628 [TBL] [Abstract][Full Text] [Related]
28. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
29. Kidney cancer: PDL1 as a biomarker in high-risk RCC. Kelsey R Nat Rev Urol; 2018 Apr; 15(4):202. PubMed ID: 29434371 [No Abstract] [Full Text] [Related]
30. Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas. Rasti A; Mehrazma M; Madjd Z; Abolhasani M; Saeednejad Zanjani L; Asgari M Sci Rep; 2018 Aug; 8(1):11739. PubMed ID: 30082842 [TBL] [Abstract][Full Text] [Related]
31. Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma. Wang C; Li Y; Chu CM; Zhang XM; Ma J; Huang H; Wang YN; Hong TY; Zhang J; Pan XW; Zheng JC; Jiang N; Hu CY; Ma X; Sun YH; Cui XG EBioMedicine; 2019 Jan; 39():255-264. PubMed ID: 30558998 [TBL] [Abstract][Full Text] [Related]
32. KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin. Fan S; Li X; Tie L; Pan Y; Li X Oncotarget; 2016 Mar; 7(12):13520-37. PubMed ID: 26575329 [TBL] [Abstract][Full Text] [Related]
33. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851 [TBL] [Abstract][Full Text] [Related]
34. Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features. Tariq N; Mamoon N; Haroon A; Ali Z; Ahmad IN J Ayub Med Coll Abbottabad; 2018; 30(3):325-332. PubMed ID: 30465359 [TBL] [Abstract][Full Text] [Related]
35. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance. Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665 [TBL] [Abstract][Full Text] [Related]
36. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. Kim K; Taylor SL; Ganti S; Guo L; Osier MV; Weiss RH OMICS; 2011 May; 15(5):293-303. PubMed ID: 21348635 [TBL] [Abstract][Full Text] [Related]
37. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis. Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469 [TBL] [Abstract][Full Text] [Related]
38. The genomics of renal cell carcinoma and its role in renal mass biopsy. Salami SS; George AK; Udager AM Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949 [TBL] [Abstract][Full Text] [Related]
39. Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241 [TBL] [Abstract][Full Text] [Related]
40. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]